On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Program Overview

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Credit Expired

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting